Cite
HARVARD Citation
Limani, P. et al. (2016). Development of OXY111A, a novel hypoxia-modifier as a potential antitumor agent in patients with hepato-pancreato-biliary neoplasms - Protocol of a first Ib/IIa clinical trial. BMC cancer. 16 (1), pp. 1-6. [Online].